Pfizer Inc (MIL:1PFE)
€ 24.62 -0.33 (-1.32%) Market Cap: 140.00 Bil Enterprise Value: 193.63 Bil PE Ratio: 34.77 PB Ratio: 1.58 GF Score: 59/100

Pfizer Inc at Barclays Global Healthcare Conference Transcript

Mar 15, 2022 / 02:45PM GMT
Carter Lewis Gould
Barclays Bank PLC, Research Division - Senior Analyst

Great. Good morning. My name is Carter Gould, senior biopharma analyst here at Barclays. I am pleased to welcome Pfizer to the stage. Today, we actually -- this is a great setup because we're going to continue the immunology theme after the last talk, and we have the entire I&I squad here from Pfizer: Michael Gladstone, Global President, Inflammation & Immunology; Michael Vincent, SVP, Chief Scientific Officer, I&I; Michael Corbo, who's Chief Development Officer in I&I.

Before we get started, Bryan Dunn from the IR team is going to make a few opening comments.

Bryan Dunn
Pfizer Inc. - Senior Director, Investor Relations

Hello, everyone. Just as a reminder, the discussion with our I&I leadership team today could include forward-looking statements. These statements are subject to risks and uncertainties that could cause actual results to differ. If you have any questions or want more information, please see our Form 10-K or 10-Q filed with the SEC. Thanks.

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot